Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
N = 46
- Population
- Patients with progressive metastatic germ cell tumours, a testicular primary and a prior complete response to first-line chemotherapy
- Design
- Single-arm trial (Clinical Trial in PubMed) of four cycles of TIP as second-line chemotherapy; eligibility required a testis primary and a prior complete response to first-line chemotherapy, both favourable prognostic factors for conventional-dose salvage.
- Arms
- TIP (experimental, n = 46): Paclitaxel, ifosfamide and cisplatin, four cycles, as second-line therapy
- People
- Kondagunta GV, senior author Motzer RJ
Show the numbers
| Endpoint | Analysis | TIP | Control | Effect |
|---|---|---|---|---|
| Complete response rateAll 46 treated patients | primaryKondagunta 2005 | 70% | — | 32 of 46 patients; 3 (7%) of those in complete response relapsed. |
| Durable complete response rateAll 46 treated patients | primarymedian follow-up 69 monthsKondagunta 2005 | 63% | — | 29 patients continuously disease-free at a median follow-up of 69 months. |
| PFSAll 46 treated patients | primaryKondagunta 2005 | 65% at 2 y (51–79%) | — | — |
| Endpoint | Analysis | TIP | Control | Effect |
|---|---|---|---|---|
| Complete response rateAll 46 treated patients | primaryKondagunta 2005 | 70% | — | 32 of 46 patients; 3 (7%) of those in complete response relapsed. |
| Durable complete response rateAll 46 treated patients | primarymedian follow-up 69 monthsKondagunta 2005 | 63% | — | 29 patients continuously disease-free at a median follow-up of 69 months. |
| PFSAll 46 treated patients | primaryKondagunta 2005 | 65% at 2 y (51–79%) | — | — |